170 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Apr 24
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
8:01am
such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Apr 24
Report of Foreign Private Issuer
8:02am
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
8:00am
such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
6-K
EX-99.1
vsd9zmcms83pq32
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
EX-99.1
9dr6il1l5
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
bkg3f16acm472q2g
7 Feb 24
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
8:02am
6-K
sxt7lehzb88jj361moth
22 Jan 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
6azda 4q012
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
wwmabv4zi 7m5
20 Dec 23
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
8:01am
6-K
EX-99.2
chb4iqv7ucyspm
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
ggl9cxsv2sd
7 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
tjw62bbp266b7qu4i2bc
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
35i2k1k wvi8be2
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
vd56x13o
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
5r06 1i4avq7d
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
xear878w3xzu1
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
EX-99.1
rc1jev
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.2
0n835aicky6gyqa
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm